---
schema_version: "secwatch.filing_event.v1"
accession: "0000929638-23-003464"
form_type: "8-K"
ticker: "ENGN"
cik: "0001980845"
company_name: "enGene Therapeutics Inc."
filed_at: "2023-12-21T23:59:59+00:00"
generated_at: "2026-06-07T09:30:25.063110+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# enGene appoints Lota Zoth to Board as Audit Committee Chair

## Summary
- Lota S. Zoth, CPA, appointed as Class I Director, effective Dec 18, 2023.
- Zoth will serve as Audit Committee Chair; Board expanded from four to five members.
- She brings 20+ years of financial and audit experience, including CFO at MedImmune.
- Currently serves on boards of Lumos Pharma, Inovio Pharmaceuticals, and 89 Bio.
- Standard independent director compensation plan applies; no related-party transactions.

## SEC filing metadata
- accession: 0000929638-23-003464
- form_type: 8-K
- ticker: ENGN
- cik: 0001980845
- company_name: enGene Therapeutics Inc.
- filed_at: 2023-12-21T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1980845/000092963823003464/0000929638-23-003464-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1980845/000092963823003464/a8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000929638-23-003464
- JSON: https://secwatch.observer/filing/0000929638-23-003464.json
- Plain text: https://secwatch.observer/filing/0000929638-23-003464.txt

## Key facts
- Executive change
  Lota Zoth was appointed as Class I Director and Audit Committee Chair at enGene Therapeutics Inc..
  - Action: appointed
  - Role: Class I Director and Audit Committee Chair
  source text: On December 18, 2023, the Board of Directors (the “Board”) of enGene Holdings Inc. (the “Company”), increased its size from four members to five and, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Lota Zoth to the Board as a Class I Director of the Board, with a term expiring at the Company’s first annual general meeting following her appointment, or until her successor is duly elected and appointed.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1980845/000092963823003464/0000929638-23-003464-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.